Filtered By:
Procedure: Transplants
Therapy: Thrombolytic Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 5 results found since Jan 2013.

Identification of characteristics, risk factors, and predictors of recurrent LVAD thrombosis: conditions in HeartWare devices
ConclusionRecurrent HVAD thrombosis mostly appears within 12  months after first thrombosis. Systemic t-PA therapy for recurrent pump thrombosis seems safe, achieving comparable effectiveness rates to initial t-PA therapy. Survival does not differ between patients with or without recurrent HVAD thrombosis.
Source: Journal of Artificial Organs - December 18, 2020 Category: Transplant Surgery Source Type: research

Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke
AbstractTreatment of acute ischemic stroke with the thrombolytic tissue plasminogen activator (tPA) can significantly improve neurological outcomes; however, thrombolytic therapy is associated with an increased risk of intra-cerebral hemorrhage (ICH). Previously, we demonstrated that during stroke tPA acting on the parenchymal side of the neurovascular unit (NVU) can increase blood –brain barrier (BBB) permeability and ICH through activation of latent platelet-derived growth factor-CC (PDGF-CC) and signaling by the PDGF receptor-α (PDGFRα). However, in vitro, activation of PDGF-CC by tPA is very inefficient and the mec...
Source: Acta Neuropathologica - July 19, 2017 Category: Neurology Source Type: research

Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms.
Authors: Francis A, Baynosa R Abstract Ischaemia-induced tissue injury has wide-ranging clinical implications including myocardial infarction, stroke, compartment syndrome, ischaemic renal failure and replantation and revascularization. However, the restoration of blood flow produces a 'second hit' phenomenon, the effect of which is greater than the initial ischaemic event and characterizes ischaemia-reperfusion (IR) injury. Some examples of potential settings of IR injury include: following thrombolytic therapy for stroke, invasive cardiovascular procedures, solid organ transplantation, and major trauma resuscitat...
Source: Diving and Hyperbaric Medicine - June 24, 2017 Category: Sports Medicine Tags: Diving Hyperb Med Source Type: research

Pathophysiologic role of ischemia reperfusion injury: a review
Publication date: Available online 19 June 2017 Source:Journal of Indian College of Cardiology Author(s): Vishal Kumar Vishwakarma, Prabhat Kumar Upadhyay, Jeetendra Kumar Gupta, Harlokesh Narayan Yadav Ischemic heart disease (IHD) is the major cause of morbidity and mortality all over the world. World health organization (WHO) in 2002 assumed that IHD may be the major leading cause of death by 2020. An estimated 17 million people died from cardiovascular diseases (CVS) globally. Of these deaths, 7 million people died by ischemia heart disease and 6.2 million by stroke. Ischemia is defined as an insufficient supply of the...
Source: Journal of Indian College of Cardiology - June 19, 2017 Category: Cardiology Source Type: research

Thrombolytic Therapy for Thrombosis of Continuous Flow Ventricular Assist Devices
Conclusions: In the setting of LVAD thrombosis, thrombolytic therapy is an alternate treatment strategy in a subset of patients. Candidacy for this alternate procedure must carefully weigh the risks of complications, including hemorrhage and thromboembolism.
Source: Journal of Cardiac Failure - December 19, 2013 Category: Cardiology Authors: Kelly Schlendorf, Chetan B. Patel, Thomas Gehrig, Todd L. Kiefer, G. Michael Felker, Adrian F. Hernandez, Laura J. Blue, Carmelo A. Milano, Joseph G. Rogers Tags: Clinical Investigations Source Type: research